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New treatment strategy for Smith- 
Lemii-Opitz syndrome
Petr Jira, Ron Wevers, Jan de Jong, Estela Rubio-Gozalbo, 
Jan Smeitink
Smith-Lemli-Opitz syndrome is caused by deficient activity of 
A7-dehydrocholesterol reductase, the final enzyme o f the 
cholesterol biosynthesis pathway, resulting in low cholesterol 
and high concentrations of its precusors, 7-dehydro cholesterol 
(7DHC) and 8DH C in blood and tissues.1'2 Cholesterol fulfils 
an essential role during embryogenesis where it functions as a 
transporter-molecule for hedgehog signalling proteins required 
for normal m orphogenesis.3 W ithout cholesterol their 
transport is impaired.3 T hese findings may explain the 
phenotypic consequences o f A7-reductase deficiency as 
observed in Smith-Lemli-Opitz syndrome: microcephaly, 
distinctive facies, organ malformations,
syndactyly/polydactyly, and genital abnormalities. O nce 
morphogenesis is complete., it is not known whether the low  
cholesterol or the increased concentration o f precursors is 
more harmful. In abetalipoproteinaemia, cholesterol 
concentrations are similar to those in Smith-Lemli-Opitz 
syndrome without clinical side-effects; we thus postulated that 
7D H C , 8D H C , or both may be the toxic substances. 
Therapeutic trials o f dietary supplementation of cholesterol 
with or without bile acids have shown that plasma cholesterol 
concentration can be increased in some patients. 
Concentrations of the precursors 7D H C  and 8D H C , however, 
were only marginally altered and clinical results so far have 
been disappointing.4,5
We performed repeated exchange transfusions in 
combination with inhibition of de-novo cholesterol synthesis 
with a HM G CoA redu etas e-inhibitor in a 3-month old girl 
with this disorder, after having obtained informed parental 
consent. This strategy aimed simultaneously to remove 
precursors while supplying extra cholesterol from the donor
Day Plasma Erythrocyte membrane
Cholesterol 7DH0 7DHC/CH Cholesterol 7DHC 
ratio
0*
38*
93
147*
190
1338(100) 
1196 (89) 
1608(120) 
2312 (173) 
2594(194)
362 ( 100) 
272(75) 
149 (41) 
191 (53) 
160 (44)
0*27
0-23
0-09
0<08
0-06
1273 (100) 
1454(114) 
1762 (138) 
2621 (206) 
2700 (212)
1087 (100) 
830(76) 
388 (36) 
470 (43) 
400 (37)
7DHC/CH
ratio
0*85
0*57
0*22
0-18
0-15
Exchange transfusions were on clays 1, 4,11, 39, 40,148,150, and 152. Slmvastin 
was begum on day 20, daily dose 0-2 mg/kg increasing to 0*4 mg/kg at day 30, and 
0*6 mg/kg from day 40. ^Immediately before exchange transfusions, CH=cholesterol; 
percentages shown in parentheses.
Gas chromatograph analysis of sterols in plasma (jxmol/L) and 
erythrocyte membrane ((xniol/60 |jiL) isolated erythrocytes 
during therapy and percentage of initial concentration
blood and inhibit renewed de-novo production of precursors at 
a higher level in the cholesterol pathway. The girl underwent 
eight whole-blood exchange transfusions during a period of 5 
months. Total exchanged volume accounted approximately for 
eight times her circulating blood volume. Oral simvastatin 
treatment was begun on day 20. N o complications or drug- 
related adverse effects were documented. Sterol plasma and 
erythrocyte-membrane concentrations during the treatment 
period of 190 days showed a substantial decrease of 7DH C  
(and 8D H C ), as well as an increase in and finally a normal 
cholesterol (table). After the first three exchange transfusions, 
plasma 7D H C  increased from 151 to 332 jimol/h over 5 days. 
After exchange transfusions four and five (days 39 and 40) 
plasma 7D H C  concentrations remained stable. M ental, 
motor, and social development improved. At age 8 months, 
the child’s neuromotor development corresponded to a child 
of 5 months on the Bayley scales of infant development. 
Measurements o f head circumference, height.» and weight 
followed the same percentages as before the start of treatment.
Repeated exchange transfusions in combination with a 
H M G  CoA-inhibitor reduced plasma and erythrocyte 
membrane precursor concentrations and improved the plasma 
7D H C /cholesterol ratio greatly in this child. W e are 
encouraged to explore the long-term effects of this treatment 
strategy as a potentially useful therapeutic option in the 
treatm ent o f young patients with Smith-Lemli-Opitz 
syndrome.
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Zolpidem in Parkinson’s disease
Antonio Daniele, Alberto Albanese, Guido Gainotti,
Bruno Gregori, Paolo Bartolomeo
Jankovic and Marsden1 suggest that drugs that enhance 
neurotransmission o f 7 -aminobutyric acid (GABA) could be 
helpful in Parkinson’s disease, but there is little evidence to 
support this claim. Zolpidem, an imidazopyridine short-acting 
hypnotic drug used to treat insomnia, shows high selectivity 
for the benzodiazepine subtype receptor BZ„ which is part of 
the GABAA-receptor complex. The highest density of 
zolpidem-binding sites is in the output structures of the basal 
ganglia: the ventral globus pallidus and the substantia nigra 
pars reticulata.2 We observed a 61-year-old woman with a 25- 
year history of Parkinson5s disease who received zolpidem for 
insomnia. After the first 10 mg dose, she showed no 
drowsiness, but a substantial improvement in akinesia and 
rigidity. Such antiparkinsonian effects were similar to those of 
levodopa. Other hypnotics (triazolam, zopiclone) were 
ineffective. This patient received zolpidem (10 mg four times 
daily) without dopaminergic drugs for 
5 years, with relief from Parkinsonian symptoms and no side- 
effects. We therefore conducted a double-blind, placebo- 
controlled crossover study of zolpidem in ten patients with 
clinically diagnosed Parkinson’s disease.3
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